Illuminating the Road Less Traveled in Biotech: Radiopharmaceuticals

This report analyzes the evolving role of radiopharmaceutical PET imaging in the diagnosis and monitoring of Alzheimer’s disease, highlighting approved and investigational amyloid-beta and tau tracers.

Key Takeaways

• 1.Radiopharmaceuticals represent a secular growth opportunity in biotech, driven by significant big pharma acquisitions and increased sales guidance for key drugs like Pluvicto.
• 2.PET imaging is crucial for the Alzheimer’s disease market, as the use of new anti-amyloid therapies like Leqembi and Kisunla requires confirmation of amyloid-beta pathology.
• 3.While blood-based biomarker tests are emerging as efficient screening tools, PET imaging remains essential for visual assessment of pathology and monitoring treatment response.

Table of Contents

• Introduction
• Background on Alzheimer's Disease
• Alzheimer's Disease Pathology
• Treatment Landscape for Alzheimer's Disease
• Investigational therapies
• The Role of Diagnostics
• Overview of the Alzheimer's Disease Imaging Market
• Amyloid-Beta PET Agents
• Tau PET Agents
• Outlook

Document Preview

Page 1 of 5

Subscribe for full accessStart Free Trial